Citations

Mayo Clinic

Showing 10 of 108602 citations.

Size-dependent differences in mitochondrial volume density in phrenic motor neurons
Fogarty, Matthew J. , Rana, Sabhya , Mantilla, Carlos B. , Sieck, Gary C. , Sieck, Gary , Mantilla, Carlos B , Rana, S , Fogarty, Matthew J

Journal of Applied Physiology | April 6, 2023 | Volume: 134 | Issue: 6 | Pages: 1332-1340

10.1152/japplphysiol.00021.2023 | PMID 37022966 Get It

Type S and FR motor units, comprising smaller phrenic motor neurons (PhMNs) are regularly activated to perform indefatigable ventilatory requirements. By contrast, type FF motor units, comprising larger PhMNs, are infrequently activated to perform expulsive straining and airway defense maneuvers. This difference in activation history is mirrored in the mitochondrial volume density (MVD), with smaller PhMNs having higher MVD than larger PhMNs. In proximal dendrites, this trend was reversed, with larger PhMNs having higher MVD than smaller PhMNs, likely due to the maintenance requirements for the larger dendritic arbor of FF PhMNs.
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies
Mesa, Ruben A. , Hudgens, Stacie , Floden, Lysbeth , Harrison, Claire , Palmer, Jeanne , Gupta, Vikas , McLornan, Donal P. , Kiladjian, Jean‐Jaques, Foltz, Lynda, Platzbecker, Uwe , Fox, María Laura , Mead, Adam J. , Perkins, Andrew C. , Leahy, Michael F. , Deheshi, Samineh, Donahue, Rafe, Klencke, Barbara , Verstovšek, Srđan , Verstovsek, Srdan , Platzbecker, Uwe , Mesa, Ruben , Mead, Adam J , McLornan, Donal , Gupta, Vikas , Perkins, Andrew C , McMullin, Mary Frances , Kiladjian, Jean‐Jacques , Ross, David M , Oh, Stephen T.

Cancer Medicine | April 6, 2023 | Volume: 12 | Issue: 9 | Pages: 10612-10624

10.1002/cam4.5799 | PMID 37021939 Get It

AbstractBackgroundMyelofibrosis (MF)‐associated constitutional symptoms can severely impact health‐related quality of life. Clinical trials in MF traditionally measure symptom response to treatment as a landmark endpoint of total symptom score (TSS) reduction ≥50% from baseline. However, this dichotomous assessment provides a limited view of clinically relevant symptomatic changes. Herein we evaluated longitudinal change from baseline in TSS over the continuous 24‐week period and individual symptom scores to obtain a more comprehensive understanding of symptom benefits experienced by patients with MF receiving therapy.MethodsLongitudinal symptom change was evaluated using mixed‐effect model repeated measure (MMRM) methodology with individual item‐level analyses to complement the interpretation of the landmark symptom results in the completed phase III SIMPLIFY studies of momelotinib in MF. MMRM compared mean change in TSS from baseline with Week 24 using data from all patient visits. Generalized estimating equations were used to estimate item‐level odds ratios using multiple predictive imputations for missing data.ResultsMomelotinib and ruxolitinib groups reported similar overall symptom improvements, with a TSS difference of <1.5 points between groups for each post‐baseline visit in SIMPLIFY‐1. In SIMPLIFY‐2, the improvement in TSS observed in momelotinib‐treated patients was consistent with that observed in SIMPLIFY‐1, whereas progressive TSS deterioration was observed with control. Item‐level scores were heterogeneous in both studies. A similar and greater proportion of momelotinib‐treated patients were categorized as “improved” or “stable” compared with control in SIMPLIFY‐1 and SIMPLIFY‐2, respectively. Odds ratios for between‐group comparison ranged from 0.75 to 1.21 in SIMPLIFY‐1, demonstrating similarity in likelihood of symptom improvement. In SIMPLIFY‐2, the likelihood of symptom improvement in each item was higher in the momelotinib arm.ConclusionsThese findings suggest that momelotinib provides clinically relevant symptom benefits in the JAK inhibitor‐naïve and JAK inhibitor‐exposed settings.
Comparison of complications for cirrhotic versus non-cirrhotic patients undergoing pancreaticoduodenectomy
Valencia, Paula Spang, Porrazzo, Gina, Almerey, Tariq , Zamorano, Alicia Amairan G. , Stauffer, John

No container title available | April 6, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2777933/v1 Get It

Abstract Purpose To compare the outcomes between patients with cirrhosis and those without who have undergone pancreatoduodenectomy (PD) in our institution. Methods A review of patients undergoing PD from the time period of January 2010 to December 2020 was performed. Patients that have undergone open or laparoscopic PD and had liver cirrhosis diagnosed prior to surgery were included and matched on a 1:2 basis with non-cirrhotic patients based on age, gender, Eastern Cooperative Oncology Group (ECOG) and date of surgery. Data was obtained from our medical records and ten major postoperative complications variables were compared to the matched group. Results Overall, 16 patients with cirrhosis were compared to 32 matched controls. No significant differences were found in pancreatic fistula (18.8% vs. 21.8%; P = 1.000), hemorrhage (6.3% vs. 6.2%; P = 1.000), delayed gastric emptying (6.3% vs. 15.6%; P = 0.648), wound infection (0% vs. 9.3%; P = 0.541) intraabdominal abscess (31.2% vs 6.2%; 0.4998) for cirrhotic vs. non-cirrhotic respectively. There were no postop ileus, gastric fistula, mesenteric portal thrombosis, biliary fistula, abdominal ischemic event in either group. The average length of stay for both groups was similar (6.9 vs. 9.3 days; P = 0.4019). There were no mortalities and major morbidity was similar (37.5% vs 34.3%;P = 0.3549). One patient required readmission for liver-related decompensation with full recovery. Conclusion PD in patients with cirrhosis can be safe and feasible in well-selected patients. In a high-volume institution, postoperative complications are similar to those patients without cirrhosis of the liver
Endometrial safety of low-dose vaginal estrogens
Matharu, Harpreet, Stanczyk, Frank Z. , Mandelbaum, Rachel S. , Dancz, Christina Elizabeth , Sherman, Mark E.

Menopause | April 6, 2023 | Volume: 30 | Issue: 6 | Pages: 650-658

10.1097/gme.0000000000002177 | PMID 37022294 Get It

Abstract It is estimated that up to 50% to 90% of postmenopausal women may experience genitourinary syndrome of menopause (GSM), which may have a detrimental impact on quality of life. One of the most effective modes of treatment of GSM is low-dose vaginal estrogens. Numerous studies have addressed the safety of these estrogens using endometrial biopsy and/or endometrial thickness on ultrasound. Based on these studies, the consensus is that low-dose vaginal estrogens do not substantially increase the risk of endometrial hyperplasia or cancer; however, the data are severely limited by short duration of follow-up. Although long-term trials are warranted, they are difficult to carry out, costly, and will not yield data for years. More immediate information regarding endometrial safety may be obtained from studies measuring endometrial tissue and serum concentrations of estradiol, estrone, and relevant equine estrogens after administration of different estrogen formulations and doses. This would allow us to understand better the metabolism of estrogens by the vagina and endometrium, and how much estrogen is reaching the endometrium. Here, we discuss metabolism, receptor binding, and signaling of estrogens in vaginal and endometrial tissue, and summarize the existing studies on the endometrial impact of low-dose vaginal estrogen treatment in postmenopausal women.
Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma
Bumma, Naresh , Dhakal, Binod , Fraser, Raphael , Estrada‐Merly, Noel, Freytes, César O. , Hildebrandt, Gerhard , Holmberg, Leona , Krem, Maxwell M. , Lekakis, Lazaros J. , Mian, Hira , Nathan, Sunita , Solh, Melhem , Strouse, Christopher , Vesole, David H. , Kumar, Shaji , Qazilbash, Muzaffar H. , Shah, Nina , Sidana, Surbhi , Holmberg, Leona , Mian, Hira , Nishihori, Taiga , Parrondo, Ricardo D , Kumar, Shaji K , Qazilbash, Muzaffar H , Shah, Nina , D'Souza, Anita , Sidana, Surbhi , Strouse, Christopher S , Dhakal, Binod , Anderson, Kenneth C. , Lee, Cindy , Lazarus, Hillard M. , Murthy, Hemant S. , Nishihori, Taiga , Patel, Sagar S. , D’Souza, Anita

Cancer | April 6, 2023 | Volume: 129 | Issue: 14 | Pages: 2179-2191

10.1002/cncr.34778 | PMID 37021929 Get It

AbstractBackgroundLenalidomide maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM) results in superior progression‐free survival and overall survival. However, patients with high‐risk multiple myeloma (HRMM) do not derive the same survival benefit from lenalidomide maintenance compared with standard‐risk patients. The authors sought to determine the outcomes of bortezomib‐based maintenance compared with lenalidomide maintenance in patients with HRMM undergoing ASCT.MethodsIn total, the authors identified 503 patients with HRMM who were undergoing ASCT within 12 months of diagnosis from January 2013 to December 2018 after receiving triplet novel‐agent induction in the Center for International Blood and Marrow Transplant Research database. HRMM was defined as deletion 17p, t(14;16), t(4;14), t(14;20), or chromosome 1q gain.ResultsThree hundred fifty‐seven patients (67%) received lenalidomide alone, and 146 (33%) received bortezomib‐based maintenance (with bortezomib alone in 58%). Patients in the bortezomib‐based maintenance group were more likely to harbor two or more high‐risk abnormalities and International Staging System stage III disease (30% vs. 22%; p = .01) compared with the lenalidomide group (24% vs. 15%; p < .01). Patients who were receiving lenalidomide maintenance had superior progression‐free survival at 2 years compared with those who were receiving either bortezomib monotherapy or combination therapy (75% vs. 63%; p = .009). Overall survival at 2 years was also superior in the lenalidomide group (93% vs. 84%; p = .001).ConclusionsNo superior outcomes were observed in patients with HRMM who received bortezomib monotherapy or (to a lesser extent) in those who received bortezomib in combination as maintenance compared with lenalidomide alone. Until prospective data from randomized clinical trials are available, post‐transplant therapy should be tailored to each patient with consideration for treating patients in clinical trials that target novel therapeutic strategies for HRMM, and lenalidomide should remain a cornerstone of treatment.
Expectations Regarding Gastein Healing Gallery Treatment and Their Connection to Health-Related Quality of Life
Toussaint, Loren , Huynh, Kien, Kohls, Niko , Sirois, Fuschia M. , Alberts, Hannah, Hanshans, Christian , Nguyen, Quang Anh , Offenbäecher, Martin, Sirois, Fuschia , Hanshans, Christian , Toussaint, Loren L , Hirsch, Jameson K. , Zee‐Neuen, Antje van der , Offenbächer, Martin

International Journal of Environmental Research and Public Health | April 6, 2023 | Volume: 20 | Issue: 7 | Pages: 5426

10.3390/ijerph20075426 | PMID 37048040 Get It

The present study examines connections between patient expectations and health-related quality of life. We explore a key distinction between expectations about general health and expectations for functional improvement. Patients were 1444 individuals with multiple conditions experiencing chronic pain who were seeking treatment at the Gastein Healing Gallery in Böckstein, near Bad Gastein, Austria. In addition to measures of expectations, patients completed measures of pain, mental and physical health, life satisfaction, fatigue, and sleep problems. Structural equation models were used to fit a latent variable model where both expectation variables were used to predict health-related quality of life. Results showed that expectations regarding potential functional improvement resulting from treatments at the Gastein Healing Gallery were associated with improved health-related quality of life. Expectations about general health improvements related to treatment were not associated with health-related quality of life. To facilitate optimal healing, clinicians may decide to emphasize expectations about functional recovery when discussing treatment methods similar to those offered at the Gastein Healing Gallery, and in so doing, health-related quality of life may benefit.
Anatomy Versus Physiology: Is Breast Lymphatic Drainage to the Internal Thoracic (Internal Mammary) Lymphatic System Clinically Relevant?
Machado, Priscilla , Liu, Ji‐Bin , Needleman, Laurence , Lee, Christine U. , Forsberg, Flemming , Lee, Christine

Journal of Breast Cancer | April 6, 2023 | Volume: 26 | Issue: 3 | Pages: 286

10.4048/jbc.2023.26.e16 | PMID 37272244 Get It

Improving the process of ordering outside genomic testing for lung cancer FNA and small biopsy specimens – A multidisciplinary quality improvement project
Nokes, Brandon , Baumann, Coralie, Magallanez, Kim, Cartin‐Ceba, Rodrigo , Spiczka, Amy Wendel, Spiczka, Amy Wendel Wendel, Chen, Longwen , Malhotra, Atul

Cytojournal | April 6, 2023 | Volume: 20 | Issue: No issue available | Pages: 8

10.25259/cytojournal_47_2021 | PMID 37151481 Get It

Objectives: Lung cancer is an important cause of mortality in the United States. Targeted mutation analysis has the potential to alter mortality in those with non-small-cell lung cancer. As such, the importance of timely tissue turnaround time (TAT) is substantial. We evaluated TAT at Mayo Clinic Arizona and found it to be delayed relative to national standards. Material and Methods: We conducted a series of plan, do, study, and act (PDSA) cycles at a single institution to identify areas for improvement with our lung cancer genomic testing. We assembled a multidisciplinary team and held serial meetings to discuss data from each PDSA cycle. Results: Using PDSA cycles and multidisciplinary discussions, we were able to identify a number of process limitations slowing TAT. We were then able to generate enhanced and timely communication between providers and pathology, educate and enforce the order/requisition workflow, and establish pathology accessioning with lung cancer specimens top priority. Conclusion: We were able to generate and implement a standard operating procedure for genomic testing of lung cancer specimens at our institution, thereby reducing tissue TAT.
Small Intestinal Bacterial Overgrowth Complicating Gastrointestinal Manifestations of Systemic Sclerosis: A Systematic Review and Meta-analysis
Pakeerathan, Veenaa, Jones, Michael P, Kashyap, Purna , Virgo, Kate, Fairlie, Thomas, Morrison, Mark , Holtmann, Gerald J, Holtmann, Gerald , Jones, Michael , Jones, Michael P , Holtmann, Gerald J , Shah, Ayesha , Jones, Michael P, Ghoshal, Uday C.

Journal of Neurogastroenterology and Motility | April 6, 2023 | Volume: 29 | Issue: 2 | Pages: 132-144

10.5056/jnm22168 | PMID 37019859 Get It

Gender bias in postgraduate year one pharmacy letters of recommendation
Drury, Anna Sahlstrom , Bookstaver, P. Brandon , Hobbs, Brandon , Leung, Jonathan G. , Moon, Jean , Nei, Scott D. , Leung, Jonathan G , Bookstaver, P Brandon , Chang, Kevin, Cook, Aaron M. , Schadler, Aric D. , Witenko, Corey J. , Bissell, Brittany D.

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | April 6, 2023 | Volume: 6 | Issue: 5 | Pages: 446-457

10.1002/jac5.1788 Get It

AbstractIntroductionLetters of recommendation (LORs) are important in pharmacy residency applications. Applicant gender, among other variables, may result in implicit biases that could impact LORs and/or residency attainment. This study hypothesized that LORs have linguistic gender differences in pharmacy residency applications.ObjectivesThe primary objective was to determine if gender‐linguistic differences exist in applicants' LORs. Gender was assessed via the pronouns utilized within the applications. The secondary outcome was to assess LOR linguistic and demographic differences between candidates who did and did not receive interviews.MethodsThis was a multiyear, multicenter study involving postgraduate year one (PGY1) applicants to participating pharmacy residency programs. Demographic data were extracted using the PhORCAS (Pharmacy Online Residency Centralized Application Service) WebADMIT (Admissions Management System) portal, and LORs were analyzed by validated linguistics processing software.ResultsA total of 7529 LORs and 2383 applicants (28.5% men, 71.5% women) were included. Women candidates had higher mean number of awards (4.71 vs. 4.1, p = 0.001) and leadership positions (4.87 vs. 4.48, p = 0.019). Compared with men candidates, women had statistically significantly higher levels of clout (p < 0.001), positive emotion (p = 0.01), social processes (p < 0.001), prosocial behavior (p = 0.002), and social referents (p < 0.001). Women also had lower authenticity compared with men candidates (p < 0.001). Two thousand and one hundred twenty applicants included in the secondary analysis found no difference in offer to interview between women and men candidates (odds ratio [OR] 1.173 [95% confidence interval (CI) 0.895–1.57], p = 0.247).ConclusionsMen and women applicants' LORS differed in specific linguistic variables, although offer to interview was not significantly different based on gender. LOR writers and programs should consider implicit biases that could affect residency offers to interview.